{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:08:48Z","timestamp":1788952128099,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T00:00:00Z","timestamp":1409616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (A\u03b2) removal, have failed to meet their primary endpoints. Neither drug improves clinical outcomes in patients with late onset AD, joining a long list of unsuccessful attempts to treat AD with anti-amyloid therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These therapies are based on the assumption that A\u03b2 accumulation is the primary pathogenic trigger of AD. Current evidence suggests that A\u03b2 may actually accumulate as part of an adaptive response to long-term chronic brain stress stimuli that would make more suitable candidates for therapeutic intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>At this juncture it is no longer unreasonable to suggest that further iterations of anti-A\u03b2 therapies should be halted. Clinicians and researchers should instead direct their attention toward greater understanding of the biological function of A\u03b2 both in healthy and demented brains, as well as the involvement of long-term chronic exposure to stress in the etiology of AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12883-014-0169-0","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T10:59:45Z","timestamp":1409569185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"14","author":[{"given":"Michaela A","family":"Castello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John David","family":"Jeppson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,2]]},"reference":[{"key":"169_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R: Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014, 370: 311-321. 10.1056\/NEJMoa1312889.","journal-title":"N Engl J Med"},{"key":"169_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR: Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med. 2014, 370: 322-333. 10.1056\/NEJMoa1304839.","journal-title":"N Engl J Med"},{"key":"169_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1056\/NEJMe1313943","volume":"370","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J: Antiamyloid therapy for Alzheimer\u2019s disease-Are we on the right road?. N Engl J Med. 2014, 370: 377-378. 10.1056\/NEJMe1313943.","journal-title":"N Engl J Med"},{"key":"169_CR4","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1212\/01.wnl.0000435556.21319.e4","volume":"81","author":"CR Jack","year":"2013","unstructured":"Jack CR, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, Mielke MM, Jones DT, Senjem ML, Gunter JL, Gregg BE, Pankratz VS, Petersen RC: Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013, 81: 1732-1740. 10.1212\/01.wnl.0000435556.21319.e4.","journal-title":"Neurology"},{"key":"169_CR5","doi-asserted-by":"publisher","first-page":"16755","DOI":"10.1523\/JNEUROSCI.4521-10.2010","volume":"30","author":"K Herrup","year":"2010","unstructured":"Herrup K: Reimagining Alzheimer\u2019s disease-an age-based hypothesis. J Neurosci. 2010, 30: 16755-16762. 10.1523\/JNEUROSCI.4521-10.2010.","journal-title":"J Neurosci"},{"key":"169_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.arr.2012.06.007","volume":"12","author":"MA Castello","year":"2013","unstructured":"Castello MA, Soriano S: Rational heterodoxy: cholesterol reformation of the amyloid doctrine. Ageing Res Rev. 2013, 12: 282-288. 10.1016\/j.arr.2012.06.007.","journal-title":"Ageing Res Rev"},{"key":"169_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.arr.2013.10.001","volume":"13C","author":"MA Castello","year":"2014","unstructured":"Castello MA, Soriano S: On the origin of Alzheimer\u2019s disease. Trials and tribulations of the amyloid hypothesis. Ageing Res Rev. 2014, 13C: 10-12. 10.1016\/j.arr.2013.10.001.","journal-title":"Ageing Res Rev"},{"key":"169_CR8","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jalz.2013.11.003","volume":"10","author":"DA Drachman","year":"2014","unstructured":"Drachman DA: The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2014, 10: 372-380. 10.1016\/j.jalz.2013.11.003.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"169_CR9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1097\/00005072-199812000-00009","volume":"57","author":"CM Hulette","year":"1998","unstructured":"Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM: Neuropathological and neuropsychological changes in \u201cnormal\u201d aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998, 57: 1168-1174. 10.1097\/00005072-199812000-00009.","journal-title":"J Neuropathol Exp Neurol"},{"key":"169_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/archneur.65.11.1509","volume":"65","author":"HJ Aizenstein","year":"2008","unstructured":"Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, Ziolko SK, James JA, Snitz BE, Houck PR, Bi W, Cohen AD, Lopresti BJ, DeKosky ST, Halligan EM, Klunk WE: Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008, 65: 1509-1517. 10.1001\/archneur.65.11.1509.","journal-title":"Arch Neurol"},{"key":"169_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ: National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement J Alzheimers Assoc. 2012, 8: 1-13. 10.1016\/j.jalz.2011.10.007.","journal-title":"Alzheimers Dement J Alzheimers Assoc"},{"key":"169_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jlcr.3158","volume":"57","author":"JP Holland","year":"2014","unstructured":"Holland JP, Liang SH, Rotstein BH, Collier TL, Stephenson NA, Greguric I, Vasdev N: Alternative approaches for PET radiotracer development in Alzheimer\u2019s disease: imaging beyond plaque. J Label Compd Radiopharm. 2014, 57: 323-331. 10.1002\/jlcr.3158.","journal-title":"J Label Compd Radiopharm"},{"key":"169_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bbr.2008.02.016","volume":"192","author":"DJ Selkoe","year":"2008","unstructured":"Selkoe DJ: Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008, 192: 106-113. 10.1016\/j.bbr.2008.02.016.","journal-title":"Behav Brain Res"},{"key":"169_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.23748","volume":"73","author":"TJ Esparza","year":"2013","unstructured":"Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL: Amyloid-\u03b2 oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013, 73: 104-119. 10.1002\/ana.23748.","journal-title":"Ann Neurol"},{"key":"169_CR15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","volume":"77","author":"S Salloway","year":"2011","unstructured":"Salloway S, Sperling R, Keren R, Porsteinsson AP, Van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM: A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011, 77: 1253-1262. 10.1212\/WNL.0b013e3182309fa5.","journal-title":"Neurology"},{"key":"169_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.neuron.2011.01.002","volume":"69","author":"TE Golde","year":"2011","unstructured":"Golde TE, Schneider LS, Koo EH: Anti-a\u03b2 therapeutics in Alzheimer\u2019s disease: the need for a paradigm shift. Neuron. 2011, 69: 203-213. 10.1016\/j.neuron.2011.01.002.","journal-title":"Neuron"},{"key":"169_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1093\/jnen\/62.11.1087","volume":"62","author":"DS Knopman","year":"2003","unstructured":"Knopman DS, Parisi JE, Salviati A, Floriach-Robert M, Boeve BF, Ivnik RJ, Smith GE, Dickson DW, Johnson KA, Petersen LE, McDonald WC, Braak H, Petersen RC: Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol. 2003, 62: 1087-1095.","journal-title":"J Neuropathol Exp Neurol"},{"key":"169_CR18","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","volume":"70","author":"H Braak","year":"2011","unstructured":"Braak H, Thal DR, Ghebremedhin E, Del Tredici K: Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100\u00a0years. J Neuropathol Exp Neurol. 2011, 70: 960-969. 10.1097\/NEN.0b013e318232a379.","journal-title":"J Neuropathol Exp Neurol"},{"key":"169_CR19","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K: Amyloid plaque core protein in Alzheimer disease and down syndrome. Proc Natl Acad Sci. 1985, 82: 4245-4249. 10.1073\/pnas.82.12.4245.","journal-title":"Proc Natl Acad Sci"},{"key":"169_CR20","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/349704a0","volume":"349","author":"A Goate","year":"1991","unstructured":"Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer\u2019s disease. Nature. 1991, 349: 704-706. 10.1038\/349704a0.","journal-title":"Nature"},{"key":"169_CR21","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/ng0892-345","volume":"1","author":"M Mullan","year":"1992","unstructured":"Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L: A pathogenic mutation for probable Alzheimer\u2019s disease in the APP gene at the N-terminus of \u03b2-amyloid. Nat Genet. 1992, 1: 345-347. 10.1038\/ng0892-345.","journal-title":"Nat Genet"},{"key":"169_CR22","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1073\/pnas.1017033108","volume":"108","author":"M Jin","year":"2011","unstructured":"Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ: Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A. 2011, 108: 5819-5824. 10.1073\/pnas.1017033108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"169_CR23","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.arr.2012.09.002","volume":"12","author":"C Li","year":"2013","unstructured":"Li C, Ebrahimi A, Schluesener H: Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer\u2019s disease. Ageing Res Rev. 2013, 12: 116-140. 10.1016\/j.arr.2012.09.002.","journal-title":"Ageing Res Rev"},{"key":"169_CR24","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1001\/jamaneurol.2013.5847","volume":"71","author":"GS Bloom","year":"2014","unstructured":"Bloom GS: Amyloid-\u03b2 and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014, 71: 505-508. 10.1001\/jamaneurol.2013.5847.","journal-title":"JAMA Neurol"},{"key":"169_CR25","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/j.neurobiolaging.2013.04.021","volume":"34","author":"EA Bignante","year":"2013","unstructured":"Bignante EA, Heredia F, Morfini G, Lorenzo A: Amyloid \u03b2 precursor protein as a molecular target for amyloid \u03b2-induced neuronal degeneration in Alzheimer\u2019s disease. Neurobiol Aging. 2013, 34: 2525-2537. 10.1016\/j.neurobiolaging.2013.04.021.","journal-title":"Neurobiol Aging"},{"key":"169_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA: Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992, 256: 184-185. 10.1126\/science.1566067.","journal-title":"Science"},{"key":"169_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, De Leon MJ, Zetterberg H: Alzheimer\u2019s disease. Lancet. 2006, 368: 387-403. 10.1016\/S0140-6736(06)69113-7.","journal-title":"Lancet"},{"key":"169_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/ng.801","volume":"43","author":"AC Naj","year":"2011","unstructured":"Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JSK, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, et al: Common variants at MS4A4\/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer\u2019s disease. Nat Genet. 2011, 43: 436-441. 10.1038\/ng.801.","journal-title":"Nat Genet"},{"key":"169_CR29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth P, Harold D, Sims R, Gerrish A, Lambert J-C, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, et al: Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat Genet. 2011, 43: 429-435. 10.1038\/ng.803.","journal-title":"Nat Genet"},{"key":"169_CR30","doi-asserted-by":"publisher","first-page":"15307","DOI":"10.1073\/pnas.1201632109","volume":"109","author":"J Bali","year":"2012","unstructured":"Bali J, Gheinani AH, Zurbriggen S, Rajendran L: Role of genes linked to sporadic Alzheimer\u2019s disease risk in the production of \u03b2-amyloid peptides. Proc Natl Acad Sci U S A. 2012, 109: 15307-15311. 10.1073\/pnas.1201632109.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"169_CR31","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0197-4580(02)00038-6","volume":"23","author":"ME Obrenovich","year":"2002","unstructured":"Obrenovich ME, Joseph JA, Atwood CS, Perry G, Smith MA: Amyloid-\u03b2: a (life) preserver for the brain. Neurobiol Aging. 2002, 23: 1097-1099. 10.1016\/S0197-4580(02)00038-6.","journal-title":"Neurobiol Aging"},{"key":"169_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/path.2885","volume":"224","author":"RJ Castellani","year":"2011","unstructured":"Castellani RJ, Smith MA: Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is \u201ctoo big to fail.\u201d. J Pathol. 2011, 224: 147-152. 10.1002\/path.2885.","journal-title":"J Pathol"},{"key":"169_CR33","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1124\/jpet.106.114009","volume":"321","author":"H Lee","year":"2007","unstructured":"Lee H, Zhu X, Castellani RJ, Nunomura A, Perry G, Smith MA: Amyloid-beta in Alzheimer disease: the null versus the alternate hypotheses. J Pharmacol Exp Ther. 2007, 321: 823-829. 10.1124\/jpet.106.114009.","journal-title":"J Pharmacol Exp Ther"},{"key":"169_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova I, Karran E, De Strooper B: The toxic A\u03b2 oligomer and Alzheimer\u2019s disease: an emperor in need of clothes. Nat Neurosci. 2012, 15: 349-357. 10.1038\/nn.3028.","journal-title":"Nat Neurosci"},{"key":"169_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1096\/fj.11-0102ufm","volume":"25","author":"VT Marchesi","year":"2011","unstructured":"Marchesi VT: Alzheimer\u2019s dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 2011, 25: 5-13. 10.1096\/fj.11-0102ufm.","journal-title":"FASEB J"},{"key":"169_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/nrn3151","volume":"13","author":"AM Stranahan","year":"2012","unstructured":"Stranahan AM, Mattson MP: Recruiting adaptive cellular stress responses for successful brain ageing. Nat Rev Neurosci. 2012, 13: 209-216.","journal-title":"Nat Rev Neurosci"},{"key":"169_CR37","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1039\/c0mb00282h","volume":"7","author":"CM Valdez","year":"2011","unstructured":"Valdez CM, Phelix CF, Smith MA, Perry G, Santamaria F: Modeling cholesterol metabolism by gene expression profiling in the hippocampus. Mol Biosyst. 2011, 7: 1891-1901. 10.1039\/c0mb00282h.","journal-title":"Mol Biosyst"},{"key":"169_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40263-013-0076-8","volume":"27","author":"J Freiherr","year":"2013","unstructured":"Freiherr J, Hallschmid M, Frey WH, Br\u00fcnner YF, Chapman CD, H\u00f6lscher C, Craft S, De Felice FG, Benedict C: Intranasal insulin as a treatment for Alzheimer\u2019s disease: a review of basic research and clinical evidence. CNS Drugs. 2013, 27: 505-514. 10.1007\/s40263-013-0076-8.","journal-title":"CNS Drugs"},{"key":"169_CR39","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3389\/fnsys.2013.00102","volume":"7","author":"J Gervain","year":"2013","unstructured":"Gervain J, Vines BW, Chen LM, Seo RJ, Hensch TK, Werker JF, Young AH: Valproate reopens critical-period learning of absolute pitch. Front Syst Neurosci. 2013, 7: 102-10.3389\/fnsys.2013.00102.","journal-title":"Front Syst Neurosci"},{"key":"169_CR40","doi-asserted-by":"publisher","first-page":"14537","DOI":"10.1523\/JNEUROSCI.2692-08.2008","volume":"28","author":"D Puzzo","year":"2008","unstructured":"Puzzo D, Privitera L, Leznik E, F\u00e0 M, Staniszewski A, Palmeri A, Arancio O: Picomolar amyloid-\u03b2 positively modulates synaptic plasticity and memory in hippocampus. J Neurosci. 2008, 28: 14537-14545. 10.1523\/JNEUROSCI.2692-08.2008.","journal-title":"J Neurosci"},{"key":"169_CR41","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1101\/lm.1310209","volume":"16","author":"A Garcia-Osta","year":"2009","unstructured":"Garcia-Osta A, Alberini CM: Amyloid beta mediates memory formation. Learn Mem. 2009, 16: 267-272. 10.1101\/lm.1310209.","journal-title":"Learn Mem"},{"key":"169_CR42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.bcp.2013.12.018","volume":"88","author":"JE Morley","year":"2014","unstructured":"Morley JE, Farr SA: The role of amyloid-beta in the regulation of memory. Biochem Pharmacol. 2014, 88: 479-485. 10.1016\/j.bcp.2013.12.018.","journal-title":"Biochem Pharmacol"},{"key":"169_CR43","first-page":"849","volume":"28","author":"W Wang","year":"2014","unstructured":"Wang W, Mutka A-L, Zmrzljak UP, Rozman D, Tanila H, Gylling H, Remes AM, Huttunen HJ, Ikonen E: Amyloid precursor protein \u03b1- and \u03b2-cleaved ectodomains exert opposing control of cholesterol homeostasis via SREBP2. FASEB J Off Publ Fed Am Soc Exp Biol. 2014, 28: 849-860.","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"169_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M: Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012, 11: 241-249. 10.1016\/S1474-4422(12)70015-7.","journal-title":"Lancet Neurol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-014-0169-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-014-0169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-014-0169-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-014-0169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:11:52Z","timestamp":1788948712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12883-014-0169-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,12]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1186\/s12883-014-0169-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,2]]},"assertion":[{"value":"5 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"169"}}